Executive Director and Chief Scientific Officer
Recce Pharmaceuticals Ltd, Australia
Ms. Dilizia stands as a co-inventor and accomplished medical scientist specialised in medical microbiology and regulatory affairs. She plays a key role in leading the research and development of the company's anti-infective compounds through the landscape of infectious diseases.
Under her guidance, Recce has developed a suite of anti-infective compounds, now protected by a robust portfolio of globally recognised patents. Her leadership has been instrumental in pushing the boundaries of innovation, receiving recognition both domestically and internationally.
One of the significant accomplishments in her career is the attainment of a Qualified Infectious Disease Product (QIDP) designation from the U.S. Food and Drug Administration (FDA). This prestigious designation underscores the therapeutic potential of Recce's compounds in addressing infectious diseases, highlighting Ms. Dilizia's contribution to the fight against antibiotic-resistant superbugs.
As a co-inventor, Ms. Dilizia's work has left a lasting impact on Recce's groundbreaking advancements. Her dual expertise seamlessly blends scientific knowledge with regulatory proficiency. In a career defined by notable achievements, Ms. Dilizia's impact coincides with Recce's commitment to providing innovative solutions in the ongoing pursuit to address the impact of infectious diseases.